ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Codexis And Dyadic Sign Enzymes Pact

by Ann M. Thayer
November 24, 2008 | APPEARED IN VOLUME 86, ISSUE 47

Codexis, a Redwood City, Calif.-based biocatalyst technology developer, has licensed Dyadic International's Chrysosporium lucknowense fungus, or C1, expression system for the large-scale production of enzymes for making biofuels and chemical and pharmaceutical intermediates. Codexis will make an up-front payment of $10 million provided that certain performance criteria are satisfied. Based in Jupiter, Fla., Dyadic produces enzymes and other biomaterials using proprietary fungal strains.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment